Compound Partnering

Compound partnering demonstrates our ability to reduce development timelines by applying proven solutions leveraged from our extensive global experience. We believe our success in compound partnering evolves from our effective contingency planning. Using our vast development experience, we are able to predict many potential outcomes and then address those potential scenarios in contingency plans that provide flexibility and the ability to adapt quickly, if necessary.

We also bridge steps in drug development by conducting earlier elements of a study while simultaneously planning for later phases of work. This strategic planning and use of best practices effectively speeds the process, enabling us to assess risks and make key decisions more quickly.

One example of the successful application of this approach is our collaboration with Syrrx, Inc./Takeda Pharmaceutical Company Limited on the development of dipeptidyl peptidase IV (DPP4) inhibitors for the treatment of type 2 diabetes. In this alliance, PPD and its partner took a compound from lead optimization to initiation of Phase III studies within just 26 months. 

Partnering Criteria

We look for compounds at pre-IND to Phase I with a straightforward, reasonably short development profile and clear regulatory path.

Why Partner With PPD?

In addition to extensive experience with alliances and a track record of successful development programs, other reasons to partner with PPD include:

• An innovative “fast and furious” approach to development
• Global development machine to pair with discovery engines
• A risk-sharing model that allows the innovator to preserve more value
• Financial strength that provides us flexibility in our approach to structuring agreements; past programs have included equity investments, co-development and in-licensed deals
• Partnered programs receive dedicated attention
• An alliance management approach based on collaboration, commitment and communication
• A focus on understanding the culture of our partners and capitalizing on complementary strengths.

PPD Pipeline

We are currently advancing four partnered compounds at various stages of development and are actively seeking additional compounds to in-license/partner.